This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere between 10% and 19.9%, depending on the drug, the Centers for Medicare & Medicaid Services announced today. 

The IRA requires drug companies to pay rebates to Medicare when prices for certain single-source and biosimilar prescription drugs covered under Part B increase faster than the rate of inflation. These 27 drugs are among the first rebatable drugs under the law. Part B drugs impacted by a coinsurance adjustment may change quarterly. For more information, see the CMS fact sheet.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Jan. 26 released proposed changes to Medicare Advantage plan capitation rates and Part D payment policies for…
Headline
The AHA Jan. 26 released a white paper on addressing challenges in implementing an advanced explanation of benefits, which requires coordination among multiple…
Headline
The AHA Jan. 26 expressed support and provided its perspective on certain provisions within the Centers for Medicare & Medicaid Services’ proposed…
Headline
The House Energy and Commerce Subcommittee on Health and Ways and Means Committee Jan. 22 hosted hearings on health care affordability that included…
Headline
The AHA Jan. 20 made recommendations to Congress on modernizing the Medicare Access and CHIP Reauthorization Act. Among the proposals, the AHA recommended…
Headline
The comment period for the Centers for Medicare & Medicaid Services' proposed rule for policies governing the Medicare Advantage and Part D programs for…